Zydus Saroglitazar PDUFA Nov 27: First PBC Drug from India

Zydus Lifesciences, an Indian pharmaceutical company traded on the National Stock Exchange of India as ZYDU.NS, has received FDA Priority Review for its New Drug Application for saroglitazar in primary biliary cholangitis (PBC). The PDUFA target action date is November 27, 2026. There is no US-listed ticker for Zydus; investors would need to access the Indian NSE for direct exposure.

This is a rare story: an Indian pharma company seeking its first major US drug approval. Zydus Therapeutics, the US subsidiary that filed the NDA, is based in Pennington, New Jersey, but the parent company is headquartered in Ahmedabad, India. The broader Zydus group (formerly Cadila Healthcare) is one of India’s largest generic drug manufacturers, but saroglitazar would be its first novel drug approved in the United States.

What the Data Showed

The Phase 3 trial compared saroglitazar to placebo in PBC patients who had an inadequate response to ursodeoxycholic acid (UDCA), the standard first-line therapy. The primary endpoint was biochemical response: 56.7% of treated patients achieved it versus 9.8% on placebo. That is a 46.9 percentage point absolute difference, a large treatment effect for a liver disease trial.

The FDA granted saroglitazar Orphan Drug Designation, Fast Track Designation, and Priority Review for PBC. The combination of all three expedited programs signals the agency recognizes the unmet need. If approved, Zydus plans a US launch by March 2027.

Saroglitazar is a dual PPAR alpha/gamma agonist. It activates both peroxisome proliferator-activated receptor alpha and gamma, modulating lipid metabolism and insulin sensitivity. This mechanism is distinct from Intercept Pharmaceuticals’ Ocaliva (obeticholic acid), an FXR agonist that has been the only second-line PBC therapy since its 2016 approval. Ocaliva carries a boxed warning for liver failure and death in advanced cirrhosis patients, a limitation that has constrained its use.

The Market Opportunity

PBC is a chronic autoimmune liver disease affecting approximately 130,000 Americans. The condition slowly destroys the small bile ducts in the liver, leading to cholestasis, fibrosis, and eventually cirrhosis or liver failure. The treatment field has been stagnant for a decade. UDCA is the standard of care but roughly 40% of patients do not respond adequately. Ocaliva is the only approved second-line option, and its boxed warning limits prescribing in advanced disease.

Saroglitazar is already approved in India for PBC, giving it real-world safety data. It was previously tested in diabetic dyslipidemia in India but never pursued in the US for that indication. The pivot to PBC as a rare disease with Orphan Drug benefits is a strategic move that gives Zydus market exclusivity and a faster regulatory path. For context on the PBC space, GSK recently received a CHMP positive opinion for Lynavoy (linerixibat) in cholestatic pruritus associated with PBC in the EU, targeting a different symptom of the same disease.

What to Watch

The November 27 PDUFA is 125 days out. The key risk is commercial, not regulatory: saroglitazar would enter a market where Ocaliva is entrenched despite its safety limitations. Convincing US hepatologists to prescribe a dual PPAR agonist from an Indian company over a known FXR agonist will require strong efficacy and safety messaging. A second risk is that the Phase 3 data, while strong on biochemical response, has not yet demonstrated long-term clinical benefit on fibrosis progression or transplant-free survival. The FDA may require post-approval studies. For background on how FDA review deadlines work, see our guide to PDUFA dates.

Source: Zydus Therapeutics NDA Priority Review press release